Prostate Cancer Screening. Dickon Hayne University of Western Australia
|
|
- Gillian Lane
- 6 years ago
- Views:
Transcription
1 Prostate Cancer Screening Dickon Hayne University of Western Australia
2 JMG Wilson & G Junger, WHO, 1968 p26-27 In theory, therefore, screening is an admirable method of combating disease, since it should help detect it in its early stages and enable it to be treated adequately before it obtains a firm hold on the community. In practice, there are snags
3 Prostate Cancer Prostate cancer is a common curable cancer that commonly doesn t require cure Autopsy study (Sakr et al J Urol 1993) 25% yr olds, 35% of yr olds had evidence of CaP Prostate cancer is the second biggest cause of male cancer related death in Australia
4 PSA Screening PSA is a serine protease produced by prostatic epithelial cells Organ specific but not cancer specific DRE and PSA combined have increased sensitivity and specificity and PPV for prostate cancer compared to DRE alone [Catalona et al Jurol 1994;151: ] Formalised population based PSA screening has yet to be adopted by any nation Currently recommended by AUA and American Cancer Society for men 50> yrs UK early detection through case finding those who present with LUTS, those who seek a test USANZ recommends PSA at 40 for well informed men who wish to reduce their chance of death from prostate cancer
5 PSA SCREENING
6 Tyrol study Natural experiment screened in Tyrol compared to unscreened in the rest of Austria 33% reduction in CaP mortality in Tyrol compared to rest of Austria where free screening and treatment available Updated analysis [Oberaigner et al Int J Public Health] Reduced prostate cancer mortality from in men >60 (risk ratio 0.7)
7 US screening study PLCO (Prostate, Lung, Colorectal and Ovarian screening trial) Andriole NEJM ,693 men Annual PSA and DRE vs. standard care (50:50) Median 11.5 year follow up 2820 cancers in screened vs 2322 in control group 92 deaths vs 82 deaths in control at 10 years Conclusion CaP death rate low and no difference between groups Criticisms 40-50% PSA and DRE testing in control arm Biopsy compliance 50% (86% in ERSPC) 44% in each arm had >1 PSA prior to entry PLCO did not comply with minimum standards for a trial i.e.having sufficient power to demonstrate an effect
8 European randomised study of screening for CaP (ERSPC) Schroeder NEJM men randomised PSA every 4 years vs. no screening. Endpoint CaP specific mortality 9 year follow up 8.2% CaP in screened vs. 4.8% non screened 0.8 times fewer deaths from CaP in screened group Need to screen 1410 men and treat 48 cases to prevent 1 death Conclusion PSA screening 20% reduction in death rate but high risk over diagnosis Criticisms Heterogenous group, PSA cut off for biopsy 2.5, 3, 10. interval 2 or 4 or 7 yrs, depending on country Need year follow up to see impact of 41% reduction in mets in screened arm ¾ TRUS biopsies were negative
9 Swedish (Goteborg) study Lancet Oncology 2010;11: Due to different legal regulations in Sweden all men could be randomised without informed consent on one day in ,000 men (10,000 each group) PSA and DRE every 2 years vs. control 14 yr follow up 1138 screened vs 718 non screened cancers 44% risk reduction in CaP mortality at 14 years Need to screen 293 men and treat 12 men to avert 1 CaP death Criticisms - PSA 2.5 for biopsy 93% men underwent biopsy if triggered by PSA
10
11 Characteristics and methodological quality of randomised controlled trials of screening for prostate cancer
12 Effects of screening on diagnosis of prostate cancer
13 Effects of screening on all cause mortality and death from prostate cancer Currently no proof that PSA screening reduces mortality from CaP
14 Cochrane Systematic review -Ilic et al BJUI Int : Identified 5 trials Serious methodological flaws in 3 Increased diagnosis of prostate cancer No difference in prostate cancer mortality
15 USA Preventive Services Taskforce (USPTSF) Reviewed same evidence as previous metaanalyses Acknowledged outcomes of ERSPC and Goteborg Concluded PSA screening resulted in a small or no difference in prostate cancer-specific mortality at 10 years and is associated with harms related to subsequent evaluation and treatment some of which may be unnecessary Recommends against PSA driven screening has provoked heavy debate and criticism
16 Conclusions PSA screening is effective in reducing the relative risk of prostate cancer death PSA screening helps to diagnose prostate cancer at an earlier stage but at the risk of over treatment and downstream adverse effects that currently cannot be precisely quantified (Responsible use of active surveillance in management of low risk prostate cancer may mitigate against the adverse affects of over diagnosis of prostate cancer)
17 What should we actually do? On basis of these findings, population/mass screening remains controversial Opportunistic screening for well informed man may be useful. What age? What interval between PSA and DRE? PSA at 40 < 1ng/ml screening interval 8 years (Schroeder 2005 from ERSPC study). PSA at 75 < 3ng/ml no need for further PSA checks as risk of dying from CaP very low (Carter 2008).
18 Melbourne Consensus Statement
19 PSA testing +/- DRE P DO I REALLY NEED THIS TEST OR PROCEDURE? Reduces you risk of dying from prostate cancer but won t necessarily make you live longer More relevany WHAT ARE THE RISKS? PSA test is safe May lead to prostate biopsy (has risks) and risks of overtreatment ARE THERE SIMPLER, SAFER OPTIONS? No WHAT HAPPENS IF I DON T DO ANYTHING? You may miss an opportunity to reduce you chance of dying from prostate cancer You may save yourself the morbidity of overtreatment of prostate cancer WHAT ARE THE COSTS? Financial costs to individual small Costs of population based screening are significant ( to society)
20 40 year old male DO I REALLY NEED THIS TEST OR PROCEDURE? WHAT ARE THE RISKS? ARE THERESIMPLER, SAFEROPTIONS? WHAT HAPPENS IF I DON TDO ANYTHING? WHAT ARE THE COSTS?
21 40 year old male (who drinks, smokes and doesn t wear a seatbelt) DO I REALLY NEED THIS TEST OR PROCEDURE? WHAT ARE THE RISKS? ARE THERE SIMPLER, SAFER OPTIONS? WHAT HAPPENS IF I DON T DO ANYTHING? WHAT ARE THE COSTS?
22 75 year old male (or anyone <7 year life expectancy) DO I REALLY NEED THIS TEST OR PROCEDURE? WHAT ARE THE RISKS? ARE THERE SIMPLER, SAFER OPTIONS? WHAT HAPPENS IF I DON TDO ANYTHING? WHAT ARE THE COSTS?
23 Male any age with LUTS Men with LUTS require: History (IPSS) Examination including DRE FFR &PVR if available or renal USS MSU PSA This is not PSA screening but the appropriate assessment of a man presenting with LUTS
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationSHARED DECISION MAKING FOR PROSTATE CANCER SCREENING
SHARED DECISION MAKING FOR PROSTATE CANCER SCREENING 16 TH A N N U A L M A S S A C H U S E T T S P R O S T A T E C A N C E R S Y M P O S I U M Mary McNaughton-Collins, MD, MPH Foundation Medical Director
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationOtis W. Brawley, MD, MACP, FASCO, FACE
Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology, Medical Oncology, Medicine and Epidemiology Emory University Atlanta, Georgia
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationResponse to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners
Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationProstate Cancer in Africa -Dilemmas in Screening & Prevention
Prostate Cancer in Africa -Dilemmas in Screening & Prevention Shingai Mutambirwa (MD) Urologist ESMO Cape Town 2017 Disclosures Adcock Ingram Allergan Astellas Astra-Zeneca Bayer Eli Lilly Ferring Janssen
More informationPoint-Counterpoint: Screening does not impact mortality rates! 1989-Fast forward, what happened?
Point-Counterpoint: Early Detection of Prostate Cancer Is Not Valuable We Can t Go Backwards Of Course Screening Has Saved Lives ~ Robert E. Donohue, MD Screening does not impact mortality rates! E. David
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationU.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017)
1 U.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017) Alex Krist MD MPH Professor and Director of Research Department of Family Medicine and Population Health
More informationMr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015
www.drjeremygrummet.com.au www.aua.com.au Mr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015 The dilemma Most men die with prostate cancer rather than
More informationManaging Prostate Cancer in General Practice
Managing Prostate Cancer in General Practice Tuesday 18 th September 2018 Presenters: Prof Jon Emery Assoc Prof Declan Murphy The education has been developed in partnership with Cancer Council Victoria,
More informationEAU 2009: US Study Shows No Mortality Benefit From Prostate Cancer Screening, But European Study Suggests There May Be One
From Medscape Medical News : www.medscape.com/viewarticle/589786 EAU 2009: US Study Shows No Mortality Benefit From Prostate Cancer Screening, But European Study Suggests There May Be One By Roxanne Nelson
More informationTranslating Evidence Into Policy The Case of Prostate Cancer Screening. Ruth Etzioni Fred Hutchinson Cancer Research Center
Translating Evidence Into Policy The Case of Prostate Cancer Screening Ruth Etzioni Fred Hutchinson Cancer Research Center Prostate Cancer Mortality in the US 2011 Prostate Cancer Mortality in the US 2011
More informationGeneral principles of screening: A radiological perspective
General principles of screening: A radiological perspective Fergus Coakley MD, Professor and Chair, Diagnostic Radiology, Oregon Health and Science University General principles of screening: A radiological
More informationScreening for prostate cancer (Review)
Ilic D, Neuberger MM, Djulbegovic M, Dahm P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 1 http://www.thecochranelibrary.com
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationCancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April Ruth Etzioni Fred Hutchinson Cancer Research Center
Cancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April 2018? Ruth Etzioni Fred Hutchinson Cancer Research Center Three thoughts to begin 1. Cancer screening is a good idea in principle Detect
More informationDecision-Analytic Modeling of PSA Screening an ONCOTYROL Project
Decision-Analytic Modeling of PSA Screening an ONCOTYROL Project EUFEP, Baden, June 24-26, 2009 Uwe Siebert, MD, MPH, MSc, ScD Professor of Public Health (UMIT) Adjunct Professor of Health Policy and Management
More informationProstate Cancer Screening: What We ve Learned and Where We Should Go
Prostate Cancer Screening: What We ve Learned and Where We Should Go Author : Gerald L. Andriole, MD Categories : Men's Health, Prevention and Screening, Prostate Cancer Tagged as : International Prostate
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationPSA & Prostate Cancer Screening
PSA & Prostate Cancer Screening DR JONATHAN REES MD MRCS MRCGP When a thing ceases to be a subject of controversy, it ceases to be a subject of interest Do you think we should have a national screening
More informationProstate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC
Prostate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC 1990 Screening The detection of disease in asymptomatic people in order to
More informationTitle: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review
Title: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review Date: November 26, 2007 Context and policy issues: Prostate cancer is the most common tumor in men, and is one of
More informationCancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies
8 ACOFP 55th Annual Convention & Scientific Seminars Cancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies Anthony
More informationPSA test. PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have:
PSA Debate PSA1 PSA2 PSA test PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have: had a DRE in the previous week. an
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More informationProstate-Specific Antigen (PSA) Screening for Prostate Cancer
Medical Coverage Policy Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 0215 Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Related
More informationContact: Linda Aagard Huntsman Cancer Institute
Contact: Linda Aagard Huntsman Cancer Institute 801-587-7639 linda.aagard@hci.utah.edu U.S. Cancer Screening Trial Reports More Diagnoses, but No Fewer Deaths from Annual Prostate Cancer Screening Huntsman
More informationResolving the PSA testing controversy. Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg
Resolving the PSA testing controversy Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg Professor Villis Marshall AC Introduc)on Guidelines aim to inform tes)ng for the
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationPSA as a Screening Test - AGP' GP's Perspective
PSA as a Screening Test - AGP' GP's Perspective Chris Del Mar cdelmar@bond.edu.auedu au Member of the RACGP Red Book Committee Background: prostate cancer is serious 9 th ranked cause of disease burden
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationPSA & Prostate Cancer Screening
PSA & Prostate Cancer Screening DR JONATHAN REES MD MRCS MRCGP Do you think we should have a national screening programme for Prostate Cancer using PSA? YES it s an outrage, women have breast cancer screening
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationPage 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!
Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationPSA-based Early Detection in the US:
PSA-based Early Detection in the US: What Went Wrong, and How to Screen Smarter Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops PAHO/WHO Consultation on
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationQuestions and Answers About the Prostate-Specific Antigen (PSA) Test
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers
More informationProstate Cancer Screening Clinical Practice Guideline. Approved by the National Guideline Directors November, 2015
Prostate Cancer Screening Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by
More informationExtent of Prostate-Specific Antigen Contamination in the Spanish Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
european urology 50 (2006) 1234 1240 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extent of Prostate-Specific Antigen Contamination in the Spanish Section
More informationMr PHIP No. 1 Prostate cancer: Should I be tested?
Mr PHIP No. 1 cancer: Should I be tested? Having a large prostate doesn t increase your chances of having prostate cancer. No. 1 / 1 Key points cancer is the most common male cancer after skin cancer.
More informationThe PSA debate. Question Answer Level of evidence and strength of recommendation
THEME: Men s health forum The PSA debate Prostate cancer 1 Routine screening for prostate cancer with digital rectal examination (DRE), serum tumour markers or transabdominal ultrasound is not recommended
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationSection Editors Robert H Fletcher, MD, MSc Michael P O'Leary, MD, MPH
1 de 32 04-05-2013 19:24 Official reprint from UpToDate www.uptodate.com 2013 UpToDate Author Richard M Hoffman, MD, MPH Disclosures Section Editors Robert H Fletcher, MD, MSc Michael P O'Leary, MD, MPH
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationTesting for. Prostate Cancer
Testing for Prostate Cancer Who this booklet is for: This booklet is to help men who do not have any symptoms decide if they want to be tested. Prostate cancer affects many men. There are tests to find
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationProstate Cancer Who needs active surveillance?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms.
More informationSelected Controversies. Cancer Screening. Breast Cancer Screening. Selected Controversies. Page 1. Using Best Evidence to Guide Practice
Cancer Screening Using Best Evidence to Guide Practice Judith M.E. Walsh, MD, MH Division of General Internal Medicine Women s Health Center of Excellence University of California, San Francisco Selected
More informationHistory of Prostate Cancer Screening and Current CUA Guidelines
History of Prostate Cancer Screening and Crrent CUA Gidelines COLIN LUNDEEN FEBRUARY 7, 2018 Objectives Review the history of prostate cancer (PCa) screening History of Prostate Specific Antigen (PSA)
More informationScreening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014
Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014 Canadian Task Force on Preventive Health Care October 2014 Putting Prevention into Practice Canadian Task
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationQuality-of-Life Effects of Prostate-Specific Antigen Screening
Quality-of-Life Effects of Prostate-Specific Antigen Screening Eveline A.M. Heijnsdijk, Ph.D., Elisabeth M. Wever, M.Sc., Anssi Auvinen, M.D., Jonas Hugosson, M.D., Stefano Ciatto, M.D., Vera Nelen, M.D.,
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationAcknowledgments: Maureen Rice, Rachel Warren, Judy Brown, Meghan Kenny, Sharon Peck-Reid, Sarah Connor Gorber
Screening for prostate cancer with prostate specific antigen and treatment of early-stage or screen-detected prostate cancer: a systematic review of the clinical benefits and harms May 2014 Lesley Dunfield
More informationUK National Screening Committee. Screening for Prostate Cancer. 19 November 2015
14/381 UK National Screening Committee Screening for Prostate Cancer 19 November 2015 Aim 1. To ask the UK National Screening Committee (UK NSC) to make a recommendation, based upon the evidence presented
More informationEpidemiologic Methods for Evaluating Screening Programs. Rosa M. Crum, MD, MHS Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationPCa Commentary. Volume 88 July - August THE VENERABLE PSA TEST: Sharpening Its Diagnostic Focus
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 88 July - August 2014 CONTENT: PSA TEST Page 1 NEW AGENTS Page 5 THE VENERABLE PSA TEST: Sharpening
More informationControversies in Breast Cancer Screening
Controversies in Breast Cancer Screening Arash Naeim, MD PhD Associate Professor of Medicine Divisions of Hematology-Oncology and Geriatric Medicine David Geffen School of Medicine University of California,
More informationCancer Screening I have no conflicts of interest. Principles of screening. Cancer in the World Page 1. Letting Evidence Be Our Guide
Cancer Screening 2012 Letting Evidence Be Our Guide Jeffrey A. Tice, MD Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Principles of screening
More informationStacy Loeb, MD Department of Urology New York University (NY, USA)
Practice-Changing Publications in Prostate Cancer: The Year in Review Stacy Loeb, MD Department of Urology New York University (NY, USA) Acknowledgement AUA Prostate Cancer Update Course William J Catalona,
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationOverdiagnosis Issues in Population-based Cancer Screening
OVERDIAGNOSIS The Balance of Benefit, Harm, and Cost of PSA Screening Grace Hui-Ming Wu, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Sam Li-Sheng Chen, Jean Chin-Yuan, Fann, Tony Hsiu-Hsi Chen 2018-09-11
More informationQuestionnaire. 1) Do you see men over the age of 40? 1. Yes 2. No
Questionnaire 1) Do you see men over the age of 40? 1. Yes 2. No 2) In what state do you practice? (drop-down menu of 50 states and District of Columbia) 3) What is your medical specialty? (Please select
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationApplying the Principles of Disease Screening to Prostate Cancer
PUBLIC HEALTH Applying the Principles of Disease Screening to Prostate Cancer Maria Paiva, BSP, PharmD, BCPS 1,2 Mary H. H. Ensom, B. Sc. (Pharm), PharmD, FASHP, FCCP, FCSHP, FCAHS 1,3 1 Faculty of Pharmaceutical
More informationPage 1. Controversies in Cancer Prevention and Screening. Disclosures. Screening. Principles of Screening. I have no conflicts of interest
Controversies in Cancer Prevention and Screening Disclosures Using the Best Evidence in 2015 I have no conflicts of interest Judith M.E. Walsh, MD, MPH Division of General Internal Medicine Women s Health
More information